274
CHIOU ET AL.
4. Bar-On P, Millard CB, Harel M, Dvir H, Enz A, Sussman JL, Silman I.
Kinetic and structural studies on the interaction of cholinesterase with
anti-Alzheimer drug rivastigmine. Biochemistry 2002;41:3555.
mates and comparison with acetylcholinesterase, cholesterol esterase,
and lipase. Chem Res Toxicol 2005;18:1124–1131.
24. Baron RL. Carbamate insecticides. In: Hayes WJJ, Laws ERJ, editors.
Handbook of pesticide toxicology, Vol.3. New York: Academic Press;
1991.
5. Harel M, Quinn DM, Nair HK, Silman I, Sussman JL. The X-ray struc-
ture of a transition state analog complex reveals the molecular origins
of the catalytic power and substrate specificity of acetylcholinesterase.
J Am Chem Soc 1996;118:2340–2346.
25. Miyazawa M, Watanabe H, Umemto K, Kameoka H. Inhibition of ace-
tylcholinesterase activity by essential oil of Mentha species. J Agric
Food Chem 1998;46:3431–3434.
6. Radic Z, Pickering NA, Vellom DC, Camp S, Taylor P. Three distinct
domains in the cholinesterase molecule confer selectivity for acetyl-
and butyrylcholinesterase inhibitors. Biochemistry 1993;32:12074–
12084.
26. Miyazawa M, Yamafuji C. Inhibition of acetylcholinesterase activity by
bicyclic monoterpenoids. J Agric Food Chem 2005;53:1765–1768.
27. Boland W, Fro¨ßl C, Lorenz N. Esterolytic and lipolytic enzymes in
organic synthesis. Synthesis 1991;12:1049–1072.
7. Taylor P, Mayer RT, Himel CM. Conformers of acetylcholinesterase:
a mechanism of allosteric control. Mol Pharmacol 1994;45:74–83.
28. Theil F. Lipase-supported synthesis of biologically active compounds.
Chem Rev 1995;95:2203–2227.
8. Pang Y-P, Quiram P, Jelacic T, Hong F, Brimjoin S. Highly potent,
selective, and low cost bis-tetrahydroaminacrine inhibitors of acetyl-
cholinesterase. Steps toward novel drugs for treating Alzheimer’s dis-
ease. J Biol Chem 1996;271:23646–23649.
29. Lin G, Chen G-H, Ho H-C. Conformationally restricted carbamate
inhibitors of horse serum butyrylcholinesterase. Bioorg Med Chem
Lett 1998;8:2747–2750.
9. Lin G, Tsai HJ, Tsai YH. Cage amines as the stopper inhibitors of
cholinesterases. Bioorg Med Chem Lett 2003;13:2887–2890.
30. Irwin AJ, Jones JB. Stereoselective horse liver alcohol dehydrogenase
catalyzed oxidoreductions of some bicyclic [2.2.1] and [3.2.1] ketones
and alcohols. J Am Chem Soc 1976;98:8476–8482.
10. Mesulam M. Neuroanatomy of cholinesterase in the normal human
brain and in Alzheimer’s disease. In: Giacobini E, editor. Cholinester-
ase and cholinesterase inhibitors. London: Martin Donitz; 2000.
p 121–137.
31. Berson JA, Walla JS, Remanick A, Suzuki S, Reynods-Warnhoff P,
Willner D. The absolute configurations of some simple norbornane
derivatives. A test of the ‘‘conformational asymmetry’’ model. J Am
Chem Soc 1961;83:3986–3997.
11. Giacobini E. Cholinergic functions in Alzheimer’s disease. Int J Ger-
iatr Psychiatry 2003;18:S1–S5.
32. Nakazaki M, Chikamatsu H, Naemura K, Asao M. Microbial stereodif-
ferentiating reduction of carbonyl compounds: proposed quadrant
rule. J Org Chem 1980;45:4432–4440.
12. Greig NH, Utsuki T, Yu Q-S, Zhu X, Holloway HW, Perry T, Lee B,
Ingram DK, Lahiri DK. A new therapeutic target in Alzheimer’s dis-
ease treatment: attention to butyrylcholinesterase. Curr Med Res
Opin 2001;17:1–6.
33. Winstein S, Trifan D. Neighboring carbon and hydrogen. XI. Solvoly-
sis of exo-norbornyl p-bromobenzenesulfonate.
J Am Chem Soc
13. Mesulam MM, Guillozet A, Shaw P, Levey A, Duysen EG, Lockridge
O. Acetylcholinesterase knockouts establish central cholinergic path-
ways and can use butyrylcholinesterase to hydrolyze acetylcholine.
Neuroscience 2002;110:627–639.
1951;74:1154–1160.
34. Yoshizako F, Nishimura A, Chubachi M, Kirihata M. Microbial reduc-
tion of 2-norbornanone by Chlorella. J Ferment Bioeng 1996;82:601–
603.
14. Giacobini E, Spiegel R, Enz A, Veroff AE, Cutler NR. Inhibition of ace-
tyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients
with Alzheimer’s disease by rivastigmine: correlation with cognitive
benefit. J Neural Transm 2002;109:1053–1065.
35. Dale JA, Mosher HS. Nuclear magnetic resonance enantiomer
reagents. Configurational correlations via nuclear magnetic resonance
chemical shifts of diastereomeric mandelate, O-methylmandelate, and
a-methoxy-a-trifluoromethylphenylacetate (MTPA) esters.
J Am
15. Yu Q-S, Holloway HW, Flippen-Anderson JL, Hoffman B, Brossi A,
Greig NH. Methyl analogues of the experimental Alzheimer’s drug
phenserine: synthesis and structure/activity relationships for acetyl-
and butyrylcholinesterase inhibitory action. J Med Chem 2001;44:
4062–4071.
Chem Soc 1973;95:512–519.
36. Takahashi T, Fukuishima A, Tanaka Y, Takeuchi Y, Kabuto K, Kabuto
C. CFTA, a new efficient agent for determination of absolute configu-
rations of chiral secondary alcohols. Chem Commun 2000:788–789.
37. Takahashi T, Kameda H, Kamei T, Ishizaki M. Synthesis of 1-fluoroin-
dan-1-carboxylic acid (FICA) and its properties as a chiral derivatizing
agent. J Fluor Chem 2006;127:760–768.
16. Bartolucci C, Perola E, Cellai L, Brufani M, Lamba D. Back door open-
ing implied by the crystal structure of a carbamoylated acetylcholines-
terase. Biochemistry 1999;38:5714–5719.
38. Ellman CL, Courtney KD, Andres VJ, Featherstone RM. A new rapid
colorimetric determination of acetylcholinesterase activity. Biochem
Pharm 1961;7:88–95.
17. Lin G, Lai C-Y, Liao W-C. Molecular recognition by acetylcholines-
terase at the peripheral anionic site: structure-activity relationships
for inhibitions by aryl carbamates. Bioorg Med Chem 1999;7:2683–
2689.
39. Hosie L, Sutton LD, Quinn DM. p-Nitrophenyl and cholesteryl-N-alkyl
carbamates as inhibitors of cholesterol esterase.
1987;262:260–264.
J Biol Chem
18. Lin G, Lai C-Y, Liao W-C, Liao P-S, Chan C-H. Structure-activity rela-
tionships as probes to the inhibition mechanisms of acetylcholinester-
ase by aryl carbamates. I. The steady-state kinetics. J Chin Chem Soc
2003;50:1259–1265.
40. Feaster SR, Lee K, Baker N, Hui DY, Quinn DM. Molecular recogni-
tion by cholesterol esterase of active site ligands: structure-reactivity
effects for inhibition by aryl carbamates and subsequent carbamylen-
zyme turnover. Biochemistry 1996;35:16723–16734.
19. Lin G. Structure-activity relationships as probes to the inhibition
mechanisms of acetylcholinesterase by aryl carbamates. II. Hammett-
Taft cross-interaction correlations. J Chin Chem Soc 2004;51:432–429.
41. Feaster SR, Quinn DM. Mechanism-based inhibitors of mammalian
cholesterol esterase. Methods Enzymol 1997;286:231–252.
20. Lin G, Liu Y-C, Lin Y-F, Wu Y-G. Ortho effects in quantitative struc-
ture-activity relationships for acetylcholinesterase inhibition by aryl
carbamates. J Enzyme Inhib Med Chem 2004;19:395–401.
42. Lin G, Lai C-Y. Hammett analysis of the inhibition of pancreatic cho-
lesterol esterase by substituted phenyl-N-butylcarbamate. Tetrahe-
dron Lett 1995;36:6117–6120.
21. Lin G, Liao W-C, Chan C-H, Wu Y-H, Tsai H-J, Hsieh C-W. Quantita-
tive structure-activity relationships for the pre-steady state acetylcho-
43. Lin G, Shieh C-T, Ho H-C, Chouhwang J-Y, Lin W-Y, Lu C-P. Struc-
ture-reactivity relationships for the inhibition mechanism at the sec-
ond alkyl-chain-binding site of cholesterol esterase and lipase. Bio-
chemistry 1999;38:9971–9981.
linesterase inhibition by carbamates.
2004;18:353–360.
J Biochem Mol Toxicol
22. Lin G, Tseng H-C, Chio A-C, Tseng T-M, Tsai B-Y. A rate determining
step change in the pre-steady state of acetylcholinesterase inhibitions
by 1,n-alkane-di-N-butycarbamates. Bioorg Med Chem Lett
2005;15:951–955.
44. Pietsch M, Gu¨tschow M. Alternate substrate inhibition of cholesterol
esterase by thieno[2,3-d][1,3]oxazin-4-ones. J Biol Chem 2002;277:
24006–24013.
45. Pietsch M, Gu¨tschow M. Synthesis of tricyclic 1,3-oxazin-4-ones and
kinetic analysis of cholesterol esterase and acetylcholinesterase inhi-
bition. J Med Chem 2005;48:8270–8288.
23. Lin G, Lee Y-R, Liu Y-C, Wu Y-G. Ortho effects for inhibition mecha-
nisms of butyrylcholinesterase by O-substituted phenyl N-butyl carba-
Chirality DOI 10.1002/chir